NO20090875L - Fusjonspeptid for inhibenng av interaksjon mellom neuronal NMDA-reseptor og NMDAR-mteragerende proteiner - Google Patents

Fusjonspeptid for inhibenng av interaksjon mellom neuronal NMDA-reseptor og NMDAR-mteragerende proteiner

Info

Publication number
NO20090875L
NO20090875L NO20090875A NO20090875A NO20090875L NO 20090875 L NO20090875 L NO 20090875L NO 20090875 A NO20090875 A NO 20090875A NO 20090875 A NO20090875 A NO 20090875A NO 20090875 L NO20090875 L NO 20090875L
Authority
NO
Norway
Prior art keywords
nmdar
fusion peptide
component
inhibiting interaction
nmda receptor
Prior art date
Application number
NO20090875A
Other languages
English (en)
Norwegian (no)
Inventor
Thomas Meyer
Original Assignee
Xigen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xigen Sa filed Critical Xigen Sa
Publication of NO20090875L publication Critical patent/NO20090875L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NO20090875A 2006-07-31 2009-02-25 Fusjonspeptid for inhibenng av interaksjon mellom neuronal NMDA-reseptor og NMDAR-mteragerende proteiner NO20090875L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06015911A EP1884521A1 (de) 2006-07-31 2006-07-31 Fusionspeptide zur Hemmung der Wechselwirkung zwischen den neuronalen NDMA Rezeptor und damit NMDAR interagierende Proteine
PCT/EP2007/006619 WO2008014917A1 (en) 2006-07-31 2007-07-25 Fusion peptide for inhibiting interaction of neuronal nmda receptor (nmdar) and nmdar interacting proteins

Publications (1)

Publication Number Publication Date
NO20090875L true NO20090875L (no) 2009-02-25

Family

ID=37084687

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090875A NO20090875L (no) 2006-07-31 2009-02-25 Fusjonspeptid for inhibenng av interaksjon mellom neuronal NMDA-reseptor og NMDAR-mteragerende proteiner

Country Status (15)

Country Link
US (1) US20090281036A1 (de)
EP (2) EP1884521A1 (de)
JP (1) JP2009545543A (de)
KR (1) KR20090033868A (de)
CN (1) CN101490081A (de)
AT (1) ATE509948T1 (de)
AU (1) AU2007280717A1 (de)
BR (1) BRPI0714783A2 (de)
CA (1) CA2653438A1 (de)
HR (1) HRP20080648A2 (de)
IL (1) IL195536A0 (de)
MX (1) MX2009001095A (de)
NO (1) NO20090875L (de)
RU (1) RU2009106710A (de)
WO (1) WO2008014917A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008008348A2 (en) * 2006-07-11 2008-01-17 Arbor Vita Corporation Method and compositions for treating stroke with fever
GB0804496D0 (en) * 2008-03-11 2008-04-16 Theryte Ltd Treating cancer
CN102088990A (zh) * 2008-05-16 2011-06-08 阿尔伯维塔公司 癫痫的治疗
CN102202677A (zh) 2008-09-03 2011-09-28 阿尔伯维塔公司 治疗疼痛的活性剂和方法
CA3018494C (en) * 2009-06-10 2021-12-07 Nono Inc. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory
PT2440230T (pt) * 2009-06-10 2021-02-03 Nono Inc Regimes de tratamento para tratamento de doenças neurológicas
ES2655112T3 (es) 2010-08-12 2018-02-16 Nono Inc. Tratamiento de una lesión penetrante en el cerebro
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2012158624A2 (en) 2011-05-13 2012-11-22 The Board Of Trustees Of The Leland Stanford Junior University Inhibitors of mitochondrial fission and methods of use thereof
EP2723363B1 (de) 2011-06-24 2018-08-29 NoNO Inc. Kombinationstherapie für ischämie
WO2013054110A2 (en) * 2011-10-10 2013-04-18 University Of Lancaster Compositions for binding to amyloid proteins
JP6279483B2 (ja) * 2011-12-13 2018-02-14 ノノ インコーポレイテッド くも膜下出血および虚血の治療法
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US10251935B2 (en) 2012-11-28 2019-04-09 Nono Inc. Lyophilized formulation comprising tat-NR2B9C, histidine and trehalose
PL2925338T3 (pl) * 2012-11-28 2019-11-29 Nono Inc Liofilizowana formulacja TAT-NR2B9C
US20140296164A1 (en) * 2013-03-29 2014-10-02 Calista Therapeutics, Inc. Compositions and methods of use for cell targeted inhibitors of the Cystic Fibrosis transmembrane regulator associated ligand
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
KR20160023669A (ko) 2013-06-26 2016-03-03 자이겐 인플라메이션 리미티드 다양한 질병의 치료를 위한 jnk 신호 전달 경로의 세포 투과성 펩타이드 억제자의 새로운 용도
JP6495270B2 (ja) 2013-10-30 2019-04-03 ザ ユニバーシティ オブ ウェスタン オーストラリア 神経保護ペプチドを含有する医薬組成物
CN103804500B (zh) * 2014-01-22 2015-12-30 广州军区广州总医院 用于治疗慢性疼痛的多肽
MX2016011517A (es) * 2014-03-07 2017-04-13 Univ Arizona Peptidos de crmp2 no narcoticos que seleccionan como diana canales de sodio para el dolor cronico.
CN103936838B (zh) * 2014-04-10 2015-10-28 武汉启瑞科技发展有限公司 小分子多肽TAT-p53DM及其在制备治疗或预防缺血性卒中药物中的应用
CN106661126B (zh) 2014-05-28 2021-12-10 诺诺公司 TAT-NR2B9c的氯盐
WO2015181757A1 (en) 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
US20170253643A1 (en) * 2014-09-02 2017-09-07 Tokyo University Of Science Foundation Centrally-Acting Peptide Derivative, and Pharmaceutical Composition
CN104650242A (zh) * 2015-01-13 2015-05-27 河南科技大学 一种融合多肽及其制备方法和应用
EP3371212B1 (de) * 2015-11-06 2023-10-11 The Board of Trustees of the University of Illinois Peptide und verfahren zur behandlung von herzstillstand
KR102253900B1 (ko) * 2016-04-27 2021-05-18 바이오셀즈(베이징) 바이오테크 코., 엘티디. 흥분성 신경독성 관련 손상 치료용 펩타이드
US11208446B2 (en) * 2016-11-01 2021-12-28 Memorial Sloan Kettering Cancer Cenier Agents and methods for treating CBP-dependent cancers
WO2018103038A1 (zh) * 2016-12-08 2018-06-14 拜西欧斯（北京）生物技术有限公司 一种缀合物及其应用
CA3094698A1 (en) * 2017-04-02 2018-10-11 Interk Peptide Therapeutics Limited Compositions and methods for prophylaxis or treatment of pain
CN110799547B (zh) * 2017-07-05 2023-02-28 拜西欧斯（北京）生物技术有限公司 用于治疗、改善或预防神经系统相关病症的化合物及其用途
BR112020000115A2 (pt) * 2017-07-05 2020-07-07 Biocells (Beijing) Biotech Co., Ltd. sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
CN112279921B (zh) 2019-07-11 2025-07-29 厦门大学 用于胞内递送分子的复合物
US20230054711A1 (en) 2019-12-31 2023-02-23 Xiamen University Multimerization delivery system for intracellular delivery of molecule
JP2023511057A (ja) * 2020-01-09 2023-03-16 ノノ インコーポレイテッド 脳卒中及び関連疾患を治療するためのプラスミン耐性ペプチド
CN113999286B (zh) * 2020-07-28 2024-08-02 中国科学院武汉病毒研究所 一种靶向肠道病毒2c蛋白的广谱抗肠道病毒的多肽抑制剂及应用
CN114539358B (zh) * 2020-11-19 2023-09-15 中国科学院大连化学物理研究所 一种多肽及制备方法与应用
CN112853559B (zh) * 2020-12-31 2021-10-08 盐城师范学院 一种基于环锭纺纱线质量的工序约束嵌套控制系统及方法
CN113735938B (zh) * 2021-07-30 2024-11-08 英纳氏(珠海)药业有限公司 一种神经保护多肽化合物及其应用
EP4458839A4 (de) * 2021-12-27 2025-11-12 Univ Ajou Ind Academic Coop Found Neuartiges zelldurchlässiges peptid und verwendung davon
CN118359717A (zh) * 2023-01-18 2024-07-19 中国科学院脑科学与智能技术卓越创新中心 抗nmda受体自身免疫性脑炎新型抗体及其用途
CN119390848A (zh) * 2023-09-07 2025-02-07 湖南中晟全肽生物科技股份有限公司 具有神经保护作用的肽及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998023781A1 (en) * 1996-11-26 1998-06-04 Johns Hopkins University Ligand detection system and methods of use thereof
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
WO2004045535A2 (en) * 2002-11-14 2004-06-03 Arbor Vita Corporation Molecular interactions in neurons

Also Published As

Publication number Publication date
WO2008014917A1 (en) 2008-02-07
MX2009001095A (es) 2009-02-10
EP2046821B1 (de) 2011-05-18
JP2009545543A (ja) 2009-12-24
RU2009106710A (ru) 2010-09-10
BRPI0714783A2 (pt) 2013-07-30
KR20090033868A (ko) 2009-04-06
EP2046821A1 (de) 2009-04-15
HRP20080648A2 (hr) 2009-02-28
EP1884521A1 (de) 2008-02-06
CN101490081A (zh) 2009-07-22
CA2653438A1 (en) 2008-02-07
AU2007280717A1 (en) 2008-02-07
IL195536A0 (en) 2011-08-01
US20090281036A1 (en) 2009-11-12
ATE509948T1 (de) 2011-06-15

Similar Documents

Publication Publication Date Title
NO20090875L (no) Fusjonspeptid for inhibenng av interaksjon mellom neuronal NMDA-reseptor og NMDAR-mteragerende proteiner
BRPI0809366B8 (pt) polipeptídeo substancialmente alfa-helicoidal, método para fabricação do mesmo, aminoácido e composição farmacêutica
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
EA200700210A1 (ru) ВАРИАНТЫ ОБЛАСТИ Fc
EP2617431A3 (de) Polypeptid-Inhibitoren von HSP27-Kinase und Verwendungen dafür
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
WO2006097536A3 (en) Dimeric peptide agonists of the glp-1 receptor
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
NO20080246L (no) Anti-IGF1R-antistofformuleringer
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
EA200802128A1 (ru) Новые нутрицевтические композиции
ATE491349T1 (de) Neue nutrazeutika-zusammensetzungen
IL223076A0 (en) Novel as160-like protein, test systems, methods and uses involving it for the identification of diabetes type 2 therapeutics
WO2006042745A3 (de) Chemisch modifizierte iapp - peptidanaloga
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
SI1848458T1 (sl) Uporaba aktiviranega polimera za ločevanje proteina in polipeptidnih multimerov
WO2008100290A3 (en) Recombinant rhinovirus vectors
WO2008081812A1 (ja) 抗腫瘍ペプチド及びその利用
AP2006003544A0 (en) Amino acids with affinity for the alpha2delta-protein.
WO2007117665A3 (en) Derivatization-enhanced analysis of amino acids and peptides
WO2006094014A3 (en) Methods for diagnosis and treatment of endometrial cancer
WO2007047962A3 (en) Insecticides that target protein kinase a (pka)
WO2007022042A3 (en) Combinations comrising a protein kinase inhibitor being a pyrimidylaminobξnzamide compound and a hsp90 inhibitor such as 17-aag
WO2004113566A3 (en) Disease related protein network
BRPI0513715A (pt) veìculo para medicamentos para obtenção de biodisponibilidade oral

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application